Thromboseprophylaxe in der muskuloskelettalen Chirurgie

Ingrid Pabinger-Fasching, Sabine Eichinger-Hasenauer, Josef Grohs, Josef Hochreiter, Norbert Kastner, Hans Christian Korninger, Sibylle Kozek-Langenecker, Stefan Marlovits, Herwig Niessner, Franz Rachbauer, Peter Ritschl, Christian Wurnig, Reinhard Windhager

Musculoskeletal surgery is associated with a high risk of venous thrombosis and pulmonary embolism. The introduction of direct oral anticoagulants (DOAK) has broadened the possibilities for prevention of venous thromboembolism in the course of orthopedic and trauma surgery. Addressing this recent development, the Austrian Societies of Orthopedics and Orthopedic Surgery (ÖGO), Trauma Surgery (ÖGU), Hematology and Oncology (OeGHO) and of Anaesthesiology, Reanimation und Intensive Care Medicine (ÖGARI) have taken the initiative to create Austrian guidelines for the prevention of thromboembolism after total hip and knee replacement, hip fracture surgery, interventions at the spine and cases of minor orthopedic and traumatic surgery. Furthermore, the pharmacology of the DOAK and the pivotal trial data for each of the three currently available substances - apixaban, dabigatran, and rivaroxaban - are briefly presented. Separate chapters are dedicated to "anticoagulation and neuroaxial anesthesia" and "bridging".